Gerresheimer Ag · XETR:GXI
Gerresheimer — FY 2025 Earnings Presentation
20 slides from Gerresheimer's earnings presentation, Jun 29, 2026
Slide 1: FY 2025 Results Presentation
FY 2025 Results Presentation 29 June 2026
Slide 2: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or
Slide 3: FY 2025 Overview
FY 2025 Overview
Slide 4: People – New Executive Board driving Governance & Transformation
People – New Executive Board driving Governance & Transformation Uwe Röhrhoff Wolf Lehmann Achim Schalk Chief Executive Officer Chief Financial Member of the (interim until 10/2026) Officer Executive Board November 2025 September 2025 November 2025 3 29-Jun-2026 Gerresheimer AG - FY 2025 Results Pre
Slide 5: Internal investigations concluded – 2025 Audited Annual Report published
Internal investigations concluded – 2025 Audited Annual Report published Improving Governance and Progressing on Transformation All accounting and governance matters thoroughly and transparently addressed – Corrections reflected in 2024 Restatement & 2025 Accounts Broad Support of Creditors (Banks,
Slide 6: 2024 restatement resulted in Revenue and EBITDA corrections
2024 restatement resulted in Revenue (minus 2%) and EBITDA (minus 7%) corrections Impact of Corrections on FY24 Sales and Adjusted EBITDA (EURm) Revenues Adj. EBITDA 2.036 1.991 419 -45 Δ45 388 Δ31 Bill and Hold -17 -31 -5 20.6% 19.5% Corrections consist of Other -27 -26 FY24 old FY24 FY24 old FY24
Slide 7: Revenue growth of 17% driven by Bormioli acquisition
Revenue growth of 17% driven by Bormioli acquisition while legacy business growth was flat - Adjusted EBITDA down by 1% despite EUR 61m contribution from Bormioli As Reported Revenues and Adjusted EBITDA; 2024 Excluding and 2025 Including Bormioli; FX As Is Revenues (EURm) Organic growth yoy1 0.3% 2
Slide 8: FY 2025 Financial Performance
FY 2025 Financial Performance
Slide 9: Sales Growth by Plastics & Devices offset by Primary Packaging Glass
Sales Growth by Plastics & Devices offset by Primary Packaging Glass; Negative EBITDA Development YoY primarily PPG FY 2025 YoY Development – Proforma like for like incl. Bormioli; FX As Is Revenues (EURm) Adj. EBITDA (EURm) Adj. EPS (EURm) Organic growth yoy1 0.3% Organic growth yoy1 -13.3% Organic
Slide 10: FY 2025 Development by Segment – Plastics and Devices
FY 2025 Development by Segment – Plastics and Devices (P&D) EBITDA remains ~flat despite revenue growth of 5% driven by Devices and Syringes In EURm Organic yoy Revenues¹ & margin +5.2%2 1,346 Revenues ▪ Increase in Syringe Systems (EUR +32m) 1,294 ▪ Medical Devices (EUR +25m) driven by ramp-up of m
Slide 11: FY 2025 Development by Segment – Primary Packaging Glass
FY 2025 Development by Segment – Primary Packaging Glas Revenue and adj. EBITDA decline mostly due to weaker market & manufacturing issues in MG In EURm Organic yoy Revenues¹ & margin 1,052 -5.5%2 Revenues ▪ Moulded Glass (EUR -52m) significant decline in demand 983 for cosmetics and oral liquids im
Slide 12: FY 2025 Cash Flow Walk
FY 2025 Cash Flow Walk Funding Transformation, Adj’ts ~70, and Interest Payments, ~100, to yield 55% EBITDA to CF 384 72 By Type 22 31 -EUR ~105m base -EUR ~190m of growth By Segment -EUR ~120m P&D Restructuring & Reorg. Payables, Supply Chain 101 -EUR ~175m PPG EUR -18m Plant & Furnace Ramp Financi
Slide 13: Financing as of Q4 2025
Financing as of Q4 2025 Compliant with leverage covenant (<5x) at Year End 2025 although suspended up and incl. Q3 2026 – Fulsome Debt Refinancing in process Net Financial Debt as of Q4 2025 Maturity Profile in EURm4 In EURm Q4 2025 Q4 2024 Revolving credit facilities1 480 0 Bridge loan / Term loans
Slide 14: Guidance & Summary
Guidance & Summary
Slide 15: Guidance Adjustment to reflect latest performance trend
Guidance Adjustment to reflect latest performance trend Adjusted FY 2026 Guidance (organic; group level) Revenue Adjusted EBITDA Free Cashflow Old New Old New Old New FY 2026 EUR 2.3- Lower Half EUR -50 ~17-18% 2.4Bn of Range to -100 m • Revenue for full year with moderate to flattish growth over 20
Slide 16: Gerresheimer Transformation Offensive key to Improve Profitability
Gerresheimer Transformation Offensive key to Improve Profitability – 2026: Initial ~EUR 10-20m equal to ~50-100bps Profitability Improvement targeted; Midterm: Accelerating 2027 onwards and targeting midterm 200-400bps Improvement Gerresheimer Transformation Offensive (gto) Capital Discipline EBITDA
Slide 17: Implemented New Segmentation incl. Moulded Glass Standalone
Implemented New Segmentation incl. Moulded Glass Standalone; Reporting 1Q onwards New Segmentation Product Groups Containment & Delivery Syst. Primary Injectable Solutions Moulded Glass Primary Packaging Plastics ~ 50% of Sales ~ 20% of Sales ~ 30% of Sales − Closures, Systems, Containers for Solid/
Slide 18: Upcoming Events
Upcoming Events Financial Reporting and Conferences Financial Calendar Investor Conferences 2026 June 29, 2026 – 15:00 Kepler Cheuvreux Autumn Conference 2026 FY 25 Conference Call CEST September 09, Paris Publication Quarterly Goldman Sachs 23rd Annual European Medtech and July/August Healthcare Se
Slide 19: Closing Remarks and Next Steps
Closing Remarks and Next Steps Key Next Steps well Defined for Execution during 2nd Half of 2026 • Centor Divestiture: Targeting Closing this year. • Debt Refinancing: Preparing Credit Ratings to approach Institutional as well as Private Debt Market; Preparation Q3 and Execution Q4 • Executing GTO t
Slide 20: innovating for a better life
innovating for a better life